ArticleBiomedical sciences instrumentation2025
INHIBITING THE INHIBITOR: WOULD TARGETING PAI-1 RESULT IN A LOW-DOSE, WELL-TOLERATED TREATMENT OF EMPYEMA?
Article in Biomedical sciences instrumentation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The incidence of empyema has continued to rise over the past several decades, and mortality rates remain up to 20-27% among patients >65 years old with comorbidities. Up to 30% of adult patients with empyema are poor candidates for both surgical treatment and conventional fibrinolytic therapy. Plasminogen activator inhibitor 1 (PAI-1) inhibits fibrinolysis, promoting pleural fibrosis and lung restriction. We hypothesized that targeting PAI-1 would result in a low-dose pharmacological treatment for empyema, improving patient survival. This hypothesis was tested in rabbit models of chemically-induced and
Indexed as
Identifiers
42232322PMC13225870What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.